Emerging Therapies in Smoldering Multiple Myeloma Show Promise but Raise Safety Concerns
Recent developments in the treatment of smoldering multiple myeloma (SMM) have shown promising results, particularly with the use of cilta-cel CAR-T cell therapy. A phase 2 trial involving 20 patients with high-risk SMM reported that all participants achieved minimal residual disease (MRD) negativity at a median follow-up of 15.3 months. However, the trial also highlighted significant safety concerns, with 35% of patients experiencing notable neurological toxicity, some with persistent symptoms. This raises questions about the risk-benefit balance of such therapies, especially since many individuals with SMM may not progress to multiple myeloma (MM). Other ongoing studies are exploring fixed-duration antibody-based immunotherapies, which have shown deep and sustained MRD negativity without neurological toxicities. 
